Literature DB >> 17487218

Marfan syndrome: clinical diagnosis and management.

John C S Dean1.   

Abstract

Marfan syndrome is a multisystem connective tissue disorder usually associated with mutation in fibrillin, and occasionally with mutation in TGFBR1 or 2. The clinical diagnosis is made using the Ghent nosology, which will unequivocally diagnose or exclude Marfan syndrome in 86% of cases. Use of a care pathway can help implementation of the nosology in the clinic. The penetrance of some features is age dependent, so the nosology must be used with caution in children. Molecular testing may be helpful in this context. The nosology cannot be used in families with isolated aortic dissection, or with related conditions such as Loeys-Dietz syndrome, although it may help identify families for further diagnostic evaluation because they do not fulfill the nosology, despite a history of aneurysm. Prophylactic medical (eg beta-blockade) and surgical intervention is important in reducing the cardiovascular complications of Marfan syndrome. Musculoskeletal symptoms are common, although the pathophysiology is less clear--for example, the correlation between dural ectasia and back pain is uncertain. Symptoms in other systems require specialist review such as ophthalmology assessment of refractive errors and ectopia lentis. Pregnancy is a time of increased cardiovascular risk for women with Marfan syndrome, particularly if the aortic root exceeds 4 cm at the start of pregnancy. High-intensity static exercise should be discouraged although low-moderate intensity dynamic exercise may be beneficial. The diagnosis and management of Marfan syndrome requires a multidisciplinary team approach, in view of its multisystem effects and phenotypic variability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487218     DOI: 10.1038/sj.ejhg.5201851

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  50 in total

Review 1.  The pathogenesis of aortopathy in Marfan syndrome and related diseases.

Authors:  Jeffrey A Jones; John S Ikonomidis
Journal:  Curr Cardiol Rep       Date:  2010-03       Impact factor: 2.931

2.  [Marfan's syndrome].

Authors:  Francisco Javier Valderrama Zurián; V Martín Gutiérrez; J V Sorlí; M Mingarro Castillo; I Ejarque Doménech; R Ortiz Uriarte; M García Ribes
Journal:  Aten Primaria       Date:  2009-05-05       Impact factor: 1.137

Review 3.  Marfan syndrome. Part 2: treatment and management of patients.

Authors:  Victoria Cañadas; Isidre Vilacosta; Isidoro Bruna; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2010-03-30       Impact factor: 32.419

Review 4.  Marfan syndrome. Part 1: pathophysiology and diagnosis.

Authors:  Victoria Cañadas; Isidre Vilacosta; Isidoro Bruna; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2010-03-30       Impact factor: 32.419

5.  Diameters of normal thoracic vascular structures in pediatric patients.

Authors:  Hatice Ozturkmen Akay; Cihan Akgul Ozmen; Aylin Hasanefendioğlu Bayrak; Senem Senturk; Selahattin Katar; Hasan Nazaroglu; Mustafa Taskesen
Journal:  Surg Radiol Anat       Date:  2009-06-25       Impact factor: 1.246

6.  [Bilateral ciliary zonule defect].

Authors:  H Neunhöffer; L Goldammer; V Gravenhorst; N Feltgen; H Hoerauf
Journal:  Ophthalmologe       Date:  2011-07       Impact factor: 1.059

Review 7.  Drug-based therapies for vascular disease in Marfan syndrome: from mouse models to human patients.

Authors:  Jason R Cook; Harikiran Nistala; Francesco Ramirez
Journal:  Mt Sinai J Med       Date:  2010 Jul-Aug

8.  Prevalence data on all Ghent features in a cross-sectional study of 87 adults with proven Marfan syndrome.

Authors:  Svend Rand-Hendriksen; Rigmor Lundby; Lena Tjeldhorn; Kai Andersen; Jon Offstad; Svein Ove Semb; Hans-Jørgen Smith; Benedicte Paus; Odd Geiran
Journal:  Eur J Hum Genet       Date:  2009-03-18       Impact factor: 4.246

9.  The many faces of aggressive aortic pathology: Loeys-Dietz syndrome.

Authors:  J J J Aalberts; M P van den Berg; J E H Bergman; G J du Marchie Sarvaas; J G Post; H van Unen; G Pals; P W Boonstra; J P van Tintelen
Journal:  Neth Heart J       Date:  2008-09       Impact factor: 2.380

10.  ENU mutagenesis reveals a novel phenotype of reduced limb strength in mice lacking fibrillin 2.

Authors:  Gaynor Miller; Monica Neilan; Ruth Chia; Nabeia Gheryani; Natalie Holt; Annabelle Charbit; Sara Wells; Valter Tucci; Zuzanne Lalanne; Paul Denny; Elizabeth M C Fisher; Michael Cheeseman; Graham N Askew; T Neil Dear
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.